CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...
Many, or all, of the products featured on this page are from our advertising partners who compensate us when you take certain actions on our website or click to take an action on their website.
BLS International Services Ltd. Board Meeting : Quarterly Results & Voluntary Delisting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback